Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Alexander G. Cumbo
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 121
- Beta
- 2.44
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 7.59
Financials
Revenue
$0.00-100.0%Net Income
$-54.80MEBITDA
$-54.01MFree Cash Flow
$-52.74MEPS (diluted)
$-0.38Shares Outstanding (diluted)
143.69M+6363.7%Operating Expenses
$57.38MCash & Debt
$377.68MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-174.32M | $-1.99 |
| 2024 | $0.00 | $-124.70M | $-3.06 |
| 2023 | $0.00 | $-96.02M | $-4.83 |
| 2022 | $8.09M | $-85.98M | $-10.10 |
| 2021 | $13.62M | $-72.19M | $-10.14 |
| 2020 | $0.00 | $-88.29M | $-25.50 |
| 2019 | $0.00 | $-117.22M | $-43.05 |
| 2018 | $0.00 | $-74.80M | $-33.73 |
| 2017 | $0.00 | $-52.12M | $-24.26 |
| 2016 | $0.00 | $-21.54M | $-16.80 |
| 2015 | $0.00 | $-6.38M | $-4.97 |
Valuation
SLDBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (2)
- Newsseekingalpha.com·6h ago·Positive
Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newsglobenewswire.com·8d ago·Neutral
Solid Biosciences to Participate at Upcoming Investor Conferences CHARLESTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 2026 Cantor Global Healthcare Conference Bo Cumbo, President and CEO, and Gabriel Books, M.D.
View source ↗
Earnings
Mon, Nov 2(in 7 weeks)
Consensus estimate $-0.37 per share
Typical surprise -11.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.38 vs $-0.46beat
- Tue, May 12$-0.52 vs $-0.40miss
- Thu, Mar 19$-0.50 vs $-0.51beat
- Mon, Nov 3$-0.48 vs $-0.42miss
- Tue, Aug 12$-0.42 vs $-0.51beat
- Thu, May 15$-0.59 vs $-0.53miss
Estimates and results for SLDB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SLDB officers and directors.
- Bought
- —
- Sold
- $2.5m
0 trades
19 trades
- Cumbo Alexandersold
- Hanrahan Jessiesold
- Ganot Ilansold
- Herzich Paulsold
- Howton David Tsold
- Tan Kevinsold
- Howton David Tsold
- Cumbo Alexandersold
80 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SLDB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.